Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone

<b>Background:</b> Prostate cancer (PCa) diagnosis remains a complex field of study. Multiparametric magnetic resonance imaging (mpMRI) technology presents opportunities to enhance diagnostic precision. While recent advances in imaging and biopsy techniques show promise, the oncological...

Full description

Saved in:
Bibliographic Details
Main Authors: Shima Tayebi, Samuel Tremblay, Jason Koehler, Alon Lazarovich, Fernando Blank, Wei-Wen Hsu, Sadhna Verma, Abhinav Sidana
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/15/6/698
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342322621284352
author Shima Tayebi
Samuel Tremblay
Jason Koehler
Alon Lazarovich
Fernando Blank
Wei-Wen Hsu
Sadhna Verma
Abhinav Sidana
author_facet Shima Tayebi
Samuel Tremblay
Jason Koehler
Alon Lazarovich
Fernando Blank
Wei-Wen Hsu
Sadhna Verma
Abhinav Sidana
author_sort Shima Tayebi
collection DOAJ
description <b>Background:</b> Prostate cancer (PCa) diagnosis remains a complex field of study. Multiparametric magnetic resonance imaging (mpMRI) technology presents opportunities to enhance diagnostic precision. While recent advances in imaging and biopsy techniques show promise, the oncological implications of prebiopsy magnetic resonance imaging (MRI) and combination biopsy (ComBx) are not fully understood. This retrospective study evaluates the potential clinical impact of prebiopsy MRI and ComBx on PCa treatment outcomes. <b>Methods:</b> We conducted a comprehensive review of treatment-naïve patients undergoing prostate biopsy and subsequent radiation therapy (RT) or radical prostatectomy at the University of Cincinnati Health Center (2014–2020). Patients were categorized into two cohorts: those with prebiopsy mpMRI and ComBx versus those with systematic biopsy (SBx) alone. Patients with prostate-specific antigen (PSA) > 20 ng/mL were excluded. Biochemical recurrence (BCR) was defined as PSA ≥ 0.2 ng/mL post-prostatectomy or ≥2 ng/mL above nadir post-RT. <b>Results:</b> This study included 518 patients (189 SBx, 329 ComBx) with a median follow-up of 19.1 months. Median patient ages were 65.9 years (SBx) and 64.6 years (ComBx). The overall BCR rate was 10% with significantly lower rates in the ComBx group compared to SBx (6.4% vs. 16.4%, <i>p</i> < 0.001). Multivariable Cox regression analysis showed patients undergoing prebiopsy mpMRI with ComBx were 63% less likely to experience BCR (HR: 0.37, 95%CI 0.20–0.70, <i>p</i> = 0.002). <b>Conclusions:</b> Prebiopsy MRI followed by ComBx demonstrated lower BCR rates, suggesting improved PCa diagnosis and risk stratification. These findings highlight the potential of advanced imaging and biopsy techniques to benefit the management of PCa. Further longitudinal studies are needed to confirm the long-term clinical benefits of this approach.
format Article
id doaj-art-cdaa993a6da54db899318a21008c00dc
institution Kabale University
issn 2075-4418
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-cdaa993a6da54db899318a21008c00dc2025-08-20T03:43:26ZengMDPI AGDiagnostics2075-44182025-03-0115669810.3390/diagnostics15060698Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy AloneShima Tayebi0Samuel Tremblay1Jason Koehler2Alon Lazarovich3Fernando Blank4Wei-Wen Hsu5Sadhna Verma6Abhinav Sidana7Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USASection of Urology, Department of Surgery, The University of Chicago Medicine & Biological Sciences, 5841 S. Maryland Ave, Rm P-217, Chicago, IL 60637, USACollege of Medicine, University of Cincinnati, Cincinnati, OH 45267, USASection of Urology, Department of Surgery, The University of Chicago Medicine & Biological Sciences, 5841 S. Maryland Ave, Rm P-217, Chicago, IL 60637, USADivision of Urology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USADivision of Biostatistics and Bioinformatics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USADepartment of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USASection of Urology, Department of Surgery, The University of Chicago Medicine & Biological Sciences, 5841 S. Maryland Ave, Rm P-217, Chicago, IL 60637, USA<b>Background:</b> Prostate cancer (PCa) diagnosis remains a complex field of study. Multiparametric magnetic resonance imaging (mpMRI) technology presents opportunities to enhance diagnostic precision. While recent advances in imaging and biopsy techniques show promise, the oncological implications of prebiopsy magnetic resonance imaging (MRI) and combination biopsy (ComBx) are not fully understood. This retrospective study evaluates the potential clinical impact of prebiopsy MRI and ComBx on PCa treatment outcomes. <b>Methods:</b> We conducted a comprehensive review of treatment-naïve patients undergoing prostate biopsy and subsequent radiation therapy (RT) or radical prostatectomy at the University of Cincinnati Health Center (2014–2020). Patients were categorized into two cohorts: those with prebiopsy mpMRI and ComBx versus those with systematic biopsy (SBx) alone. Patients with prostate-specific antigen (PSA) > 20 ng/mL were excluded. Biochemical recurrence (BCR) was defined as PSA ≥ 0.2 ng/mL post-prostatectomy or ≥2 ng/mL above nadir post-RT. <b>Results:</b> This study included 518 patients (189 SBx, 329 ComBx) with a median follow-up of 19.1 months. Median patient ages were 65.9 years (SBx) and 64.6 years (ComBx). The overall BCR rate was 10% with significantly lower rates in the ComBx group compared to SBx (6.4% vs. 16.4%, <i>p</i> < 0.001). Multivariable Cox regression analysis showed patients undergoing prebiopsy mpMRI with ComBx were 63% less likely to experience BCR (HR: 0.37, 95%CI 0.20–0.70, <i>p</i> = 0.002). <b>Conclusions:</b> Prebiopsy MRI followed by ComBx demonstrated lower BCR rates, suggesting improved PCa diagnosis and risk stratification. These findings highlight the potential of advanced imaging and biopsy techniques to benefit the management of PCa. Further longitudinal studies are needed to confirm the long-term clinical benefits of this approach.https://www.mdpi.com/2075-4418/15/6/698prostate cancermagnetic resonance imagingoncological outcomesbiochemical failure
spellingShingle Shima Tayebi
Samuel Tremblay
Jason Koehler
Alon Lazarovich
Fernando Blank
Wei-Wen Hsu
Sadhna Verma
Abhinav Sidana
Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
Diagnostics
prostate cancer
magnetic resonance imaging
oncological outcomes
biochemical failure
title Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
title_full Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
title_fullStr Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
title_full_unstemmed Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
title_short Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
title_sort prebiopsy magnetic resonance imaging followed by combination biopsy for prostate cancer diagnosis is associated with a lower risk of biochemical failure after treatment compared to systematic biopsy alone
topic prostate cancer
magnetic resonance imaging
oncological outcomes
biochemical failure
url https://www.mdpi.com/2075-4418/15/6/698
work_keys_str_mv AT shimatayebi prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT samueltremblay prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT jasonkoehler prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT alonlazarovich prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT fernandoblank prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT weiwenhsu prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT sadhnaverma prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone
AT abhinavsidana prebiopsymagneticresonanceimagingfollowedbycombinationbiopsyforprostatecancerdiagnosisisassociatedwithalowerriskofbiochemicalfailureaftertreatmentcomparedtosystematicbiopsyalone